Sign in

John A. Paulson

Director at Bausch & Lomb
Board

About John A. Paulson

Independent director of Bausch + Lomb (BLCO) since April 2022; age 69. President and Portfolio Manager at Paulson Capital Inc.; previously founded and led Paulson & Co. Inc., with prior senior roles at Gruss Partners and Bear Stearns. He holds a finance degree from NYU (1978) and an MBA from Harvard Business School (1980). In 2024 he attended 100% of Board meetings (8/8) and 100% of Nominating & Corporate Governance Committee meetings (4/4) .

Past Roles

OrganizationRoleTenureCommittees/Impact
Paulson Capital Inc.President, Portfolio Manager, DirectorCurrentInvestment strategy, mergers, event arbitrage, credit
Paulson & Co. Inc.President, Portfolio Manager, Founder1994–priorFounded firm; led investment activities
Gruss PartnersPartnerPrior to 1994M&A and investing
Bear StearnsManaging Director, M&APrior to 1994Corporate finance, transaction execution

External Roles

OrganizationRoleStatusNotes
Bausch Health Companies Inc. (BHC)Chairman of the BoardCurrent (rejoined June 2022)BLCO’s controlling shareholder; cross-directorship
Acadian Asset Management Inc. (formerly BrightSphere Investment Group plc)Director; Chairman since April 2020CurrentPublic asset manager
Steinway Musical Instruments, Inc.Chairman; majority ownerPrivateBoard leadership and ownership
P.F. Chang’sChairman; majority ownerPrivateBoard leadership and ownership
American International Group, Inc.Director2016–2017Prior public company directorship

Board Governance

  • Independence: Determined independent under U.S. and Canadian rules; BLCO’s board is 90% independent (9 of 10 directors) .
  • Committees: Member, Nominating & Corporate Governance Committee (Chair: Thomas W. Ross Sr.). Not on Audit & Risk, Talent & Compensation, or Science & Technology .
  • Attendance: 2024 Board 8/8; Nominating & Corporate Governance 4/4; overall 12/12 (100%) .
  • Executive sessions: Independent directors met in executive session at each of the four regular Board meetings in 2024 (presided by Lead Independent Director) .
  • Tenure: Three full years of service as of March 24, 2025 .

Fixed Compensation

Component (2024)AmountDetail
Board/Committee cash fees$43,750Paulson elected RSUs for Q1–Q2; cash in Q3–Q4 per program
Annual equity retainer (RSUs)$283,72014,696 RSUs granted for 2024; grant-date fair value
Total BLCO director compensation$327,470Sum of cash and stock awards
BHC director compensation (for service on BHC board)$500,000 (stock awards)Additional compensation from parent board

Program structure for non-employee directors:

  • $80,000 annual cash retainer; $240,000 target annual RSU grant; Lead Independent Director $40,000; Committee chair/member retainers (Audit chair $25,000; Nominating chair $15,000; Talent chair $20,000; members $7,500–$12,500); annual director total cap $750,000 .

Performance Compensation

Directors do not receive performance-based equity; RSUs are time-based. For context on BLCO’s pay-for-performance oversight (executive program):

  • Annual Incentive Program metrics: Adjusted EBITDA (60%) and Revenues (40%); 2024 funding certified at 107% .
  • PSU metrics: Organic revenue growth thresholds (4.5%→50%; 6%→100%; 7%→200%) and rTSR percentiles (30th→50%; 50th→100%; 80th→200%) .
  • Outperformance PSU modifier (rTSR-based) and negative absolute TSR cap at 50% .

Other Directorships & Interlocks

CompanyRelationship to BLCOInterlock Risk
Bausch Health Companies Inc. (BHC)Controls 87.88% of BLCO shares (353,273,183 outstanding; BHC holds 310,449,643)Paulson chairs BHC; cross-directorship may pose perceived influence on BLCO governance
Icahn Group agreementDirector Appointment & Nomination Agreement grants Icahn Designee rights over board seats/committee participation; constraints on rights plansHeightened shareholder influence and structural constraints noted; not directly tied to Paulson but relevant to board dynamics

Related-party oversight and transactions:

  • Audit & Risk Committee reviews director conflicts; directors must recuse from voting on interested transactions .
  • April 2025: BHC paid BLCO $14.7 million to terminate an indemnification arrangement under the Master Separation Agreement; otherwise no related-party transactions since Jan 1, 2024 .

Expertise & Qualifications

  • Financial and investment strategy expertise (mergers, event arbitrage, credit) with SEC-registered firm leadership .
  • Public company governance experience (BHC chair; AIG director; Acadian director/chair) .
  • Education: NYU finance (1978), Harvard MBA (1980) .

Equity Ownership

MetricValueNotes
BLCO common shares owned25,357As of March 24, 2025
Vested RSUs (settlement deferred)7,687As of Dec 31, 2024
Unvested RSUs14,696Annual equity retainer; vests prior to next annual meeting unless deferred
Total equity value at risk$525,730Includes common shares and vested RSUs; excludes unvested RSUs/options
Ownership vs guideline131% of $400,000 requirementDirector guideline = 5× $80,000 cash retainer; compliance assessed
Ownership as % of shares outstanding~0.0072% (25,357 / 353,273,183 )Based on outstanding shares at 3/24/2025
Hedging/PledgingProhibited; none of NEOs/directors hold margin/pledged accountsAnti-hedging/anti-pledging policies; no exceptions for directors

Governance Assessment

  • Strengths

    • Independent status with perfect 2024 attendance and service on Nominating & Corporate Governance; signals strong engagement .
    • Material personal ownership above director guideline; deferred RSU settlement enhances alignment .
    • Board maintains robust governance practices (executive sessions; annual evaluations; independent compensation consultant; anti-hedging/pledging; clawbacks for officers) .
  • Potential red flags / monitoring points

    • Cross-directorship: Chair of BHC, BLCO’s controlling shareholder (87.88%)—perceived influence risk; continue monitoring related-party arrangements and committee independence .
    • Structural shareholder rights via Icahn Group agreement may constrain board actions and committee composition; consider implications for independent oversight .
  • Market/compensation signals

    • Company say-on-pay support ~95% in 2024 indicates investor confidence in compensation governance (relevant to board oversight) .
    • Company TSR since IPO: $90.30 vs peer group $93.86 as of 12/31/2024—neutral to slightly lagging; not attributable to any one director but relevant to oversight focus .

Appendix: Committee Assignments (2024)

CommitteeMembersChairMeetings
Nominating & Corporate GovernanceThomas W. Ross Sr.; Sarah B. Kavanagh; John A. Paulson; Andrew C. von Eschenbach, M.D.Thomas W. Ross Sr.4
Audit & RiskSarah B. Kavanagh; Nathalie Bernier; Gary Hu; Russel C. RobertsonSarah B. Kavanagh8
Talent & CompensationKaren L. Ling; Gary Hu; Russel C. Robertson; Thomas W. Ross Sr.Karen L. Ling6
Science & TechnologyAndrew C. von Eschenbach, M.D.; Nathalie Bernier; Gary HuAndrew C. von Eschenbach, M.D.4